[go: up one dir, main page]

MA24581A1 - Procede de preparation de composes utiles pour le traitement de la resistance a l'insuline . - Google Patents

Procede de preparation de composes utiles pour le traitement de la resistance a l'insuline .

Info

Publication number
MA24581A1
MA24581A1 MA25139A MA25139A MA24581A1 MA 24581 A1 MA24581 A1 MA 24581A1 MA 25139 A MA25139 A MA 25139A MA 25139 A MA25139 A MA 25139A MA 24581 A1 MA24581 A1 MA 24581A1
Authority
MA
Morocco
Prior art keywords
preparation
treatment
insulin resistance
compounds useful
compounds
Prior art date
Application number
MA25139A
Other languages
English (en)
Inventor
Philip Albert Carpino
Charles Kwok-Fung Chiu
Bruce Allen Lefker
Lydia Codetta Pan
Judith Lee Treadway
Michael Paul Zawistoski
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA24581A1 publication Critical patent/MA24581A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
MA25139A 1997-06-25 1998-06-24 Procede de preparation de composes utiles pour le traitement de la resistance a l'insuline . MA24581A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5079097P 1997-06-25 1997-06-25

Publications (1)

Publication Number Publication Date
MA24581A1 true MA24581A1 (fr) 1998-12-31

Family

ID=21967444

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25139A MA24581A1 (fr) 1997-06-25 1998-06-24 Procede de preparation de composes utiles pour le traitement de la resistance a l'insuline .

Country Status (40)

Country Link
US (3) US6448263B1 (fr)
EP (1) EP1000085B1 (fr)
JP (2) JP2000514099A (fr)
KR (1) KR20010014224A (fr)
CN (2) CN1152049C (fr)
AP (1) AP1145A (fr)
AR (1) AR012256A1 (fr)
AT (1) ATE305477T1 (fr)
AU (1) AU747510B2 (fr)
BG (1) BG104008A (fr)
BR (1) BR9810477A (fr)
CA (1) CA2294464A1 (fr)
CO (1) CO4950621A1 (fr)
DE (1) DE69831745T2 (fr)
DZ (1) DZ2539A1 (fr)
EA (1) EA002089B1 (fr)
EG (1) EG21712A (fr)
ES (1) ES2248899T3 (fr)
HN (1) HN1998000088A (fr)
HR (1) HRP980361A2 (fr)
HU (1) HUP0001922A3 (fr)
ID (1) ID24345A (fr)
IL (7) IL154116A0 (fr)
IN (1) IN189724B (fr)
IS (1) IS5275A (fr)
MA (1) MA24581A1 (fr)
NO (1) NO996205L (fr)
NZ (1) NZ500655A (fr)
OA (1) OA11242A (fr)
PA (1) PA8452601A1 (fr)
PE (1) PE105399A1 (fr)
PL (1) PL337659A1 (fr)
SK (1) SK175699A3 (fr)
TN (1) TNSN98113A1 (fr)
TR (1) TR199903257T2 (fr)
TW (1) TW553943B (fr)
UA (1) UA64751C2 (fr)
WO (1) WO1998058949A1 (fr)
YU (1) YU70199A (fr)
ZA (1) ZA985546B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
US6541634B2 (en) * 1999-02-26 2003-04-01 Pfizer Inc. Process for preparing growth hormone secretagogues
US7721948B1 (en) * 1999-05-25 2010-05-25 Silverbrook Research Pty Ltd Method and system for online payments
EP1132388A3 (fr) * 2000-03-09 2004-03-03 Pfizer Products Inc. Métabolites de hexahydropyrazolo[4,3-c]pyridines
ES2333097T3 (es) 2000-05-31 2010-02-17 Raqualia Pharma Inc Uso de secretagogos de la hormona de crecimiento para estimular la motilidad gastrointestinal.
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
US20060128615A1 (en) * 2002-09-18 2006-06-15 Pierrette Gaudreau Ghrh analogues
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
BRPI0519728B1 (pt) * 2004-12-21 2016-12-13 Hercules Inc resinas catiônicas reativas e processo de fabricação de papel
US20070024388A1 (en) * 2005-07-27 2007-02-01 Hassan Tanbakuchi Slabline structure with rotationally offset ground
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
ES2604943T3 (es) 2007-02-09 2017-03-10 Ocera Therapeutics, Inc. Moduladores macrocíclicos del receptor de la grelina y procedimientos de uso de los mismos
US7862825B2 (en) * 2007-02-21 2011-01-04 Mladen Vranic Method of controlling tight blood glucose by somatostatin receptor antagonists
RU2403902C1 (ru) * 2009-06-15 2010-11-20 Илья Николаевич Медведев Способ снижения биологического возраста при нарушении толерантности к глюкозе
US8546416B2 (en) 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
KR20150003771A (ko) 2012-05-03 2015-01-09 노파르티스 아게 그렐린 수용체 효능제로서의 2,7-디아자-스피로[4.5]데스-7-일 유도체의 l-말레이트 염 및 그의 결정질 형태
ES2678020T3 (es) * 2013-05-28 2018-08-08 Raqualia Pharma Inc. Formas polimórficas
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
MX377481B (es) * 2014-08-05 2025-03-07 Raqualia Pharma Inc Derivados de serina como agonistas del receptor de grelina.
WO2016067638A1 (fr) * 2014-10-31 2016-05-06 Raqualia Pharma Inc. Dérivés tétrahydropyrazolopyridines utiles en tant qu'agonistes du récepteur de la ghréline
WO2017075535A1 (fr) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Méthodes de traitement de troubles neurodégénératifs
WO2024217441A1 (fr) * 2023-04-21 2024-10-24 长春金赛药业有限责任公司 Agoniste de ghsr 1a, composition pharmaceutique et son procédé de préparation et son utilisation
CN119285632A (zh) * 2024-10-09 2025-01-10 威海中腾医药科技有限公司 一种基于酵母醇脱氢酶催化氧化的卡普瑞林中间体的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3235550A (en) 1966-02-15 Anal g gesiaxoat t tail intravenous injection
US3190802A (en) 1961-10-09 1965-06-22 Boehringer Sohn Ingelheim Shaving composition and method of using same
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
GB2101114B (en) 1981-07-10 1985-05-22 Farmos Group Ltd Substituted imidazole derivatives and their preparation and use
US5242783A (en) 1991-07-31 1993-09-07 Eastman Kodak Company Photographic material and process
AU676525B2 (en) 1992-11-06 1997-03-13 Merck & Co., Inc. Substituted dipeptide analogs promote release of growth hormone
HUT72076A (en) 1992-12-11 1996-03-28 Merck & Co Inc Process for preparing spiro piperidines and homologs which promote release of growth hormone and pharmaceutical compositions containing them
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
WO1995013069A1 (fr) 1993-11-09 1995-05-18 Merck & Co., Inc. Piperidines, pyrrolidines et hexahydro-1h-azepines favorisant la liberation de l'hormone de croissance
BR9610277A (pt) 1995-08-31 1999-07-06 Schering Corp Derivados de piperazino como antagonistas de neurowuinina
EP0766966A3 (fr) * 1995-09-08 2001-02-28 Eli Lilly And Company Méthode de traitement de la résistance à l'insuline
PL327227A1 (en) 1995-12-22 1998-12-07 Novo Nordisk As Compounds exhibiting growth hormone liberating properties
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
ATE356139T1 (de) * 1997-06-25 2007-03-15 Pfizer Dipeptidderivate zur förderung der sekretion von wachstumshormon
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)

Also Published As

Publication number Publication date
IL154114A0 (en) 2003-07-31
IL154116A0 (en) 2003-07-31
IL156465A0 (en) 2004-01-04
HN1998000088A (es) 1999-01-08
ES2248899T3 (es) 2006-03-16
NO996205D0 (no) 1999-12-15
AP1145A (en) 2003-02-14
EP1000085B1 (fr) 2005-09-28
JP2005097261A (ja) 2005-04-14
HUP0001922A2 (hu) 2000-12-28
IL154112A0 (en) 2003-07-31
EP1000085A1 (fr) 2000-05-17
US6448263B1 (en) 2002-09-10
EA199901075A1 (ru) 2000-08-28
HK1028051A1 (en) 2001-02-02
PA8452601A1 (es) 2000-05-24
ZA985546B (en) 2000-01-10
HRP980361A2 (en) 1999-02-28
IL156465A (en) 2004-07-25
TR199903257T2 (xx) 2000-12-21
EA002089B1 (ru) 2001-12-24
CA2294464A1 (fr) 1998-12-30
HUP0001922A3 (en) 2001-02-28
AP9801267A0 (en) 1998-06-30
IL133626A0 (en) 2001-04-30
UA64751C2 (uk) 2004-03-15
TNSN98113A1 (fr) 2005-03-15
CN1152049C (zh) 2004-06-02
PL337659A1 (en) 2000-08-28
YU70199A (sh) 2003-01-31
IL154115A0 (en) 2003-07-31
IN189724B (fr) 2003-04-19
AU7445698A (en) 1999-01-04
NZ500655A (en) 2002-02-01
BR9810477A (pt) 2007-05-22
DE69831745D1 (de) 2006-02-09
DE69831745T2 (de) 2006-08-31
US6867202B1 (en) 2005-03-15
US20030100561A1 (en) 2003-05-29
CN1259140A (zh) 2000-07-05
WO1998058949A1 (fr) 1998-12-30
TW553943B (en) 2003-09-21
BG104008A (en) 2000-07-31
JP2000514099A (ja) 2000-10-24
AR012256A1 (es) 2000-09-27
CN1530107A (zh) 2004-09-22
OA11242A (en) 2003-07-23
US6630487B2 (en) 2003-10-07
IL154111A0 (en) 2003-07-31
NO996205L (no) 1999-12-15
CO4950621A1 (es) 2000-09-01
DZ2539A1 (fr) 2003-02-08
EG21712A (en) 2002-02-27
ATE305477T1 (de) 2005-10-15
KR20010014224A (ko) 2001-02-26
JP3742643B2 (ja) 2006-02-08
IS5275A (is) 1999-11-26
AU747510B2 (en) 2002-05-16
SK175699A3 (en) 2001-04-09
ID24345A (id) 2000-07-13
PE105399A1 (es) 1999-11-04

Similar Documents

Publication Publication Date Title
MA24581A1 (fr) Procede de preparation de composes utiles pour le traitement de la resistance a l'insuline .
MA23270A1 (fr) Procede pour la preparation de nouveaux composes.
MA22922A1 (fr) Procede pour la preparation de nouveaux composes .
MA22626A1 (fr) Procede de preparation d'acides imidazolyl-alcenoiques .
MA22668A1 (fr) Procede de preparation d'oxamides .
MA22481A1 (fr) Procede de preparation d'acides imidazolyl - alcenoiques .
FR2740132B1 (fr) Procede pour la preparation de 1,1,1,3,3-pentafluoropropane
MA25223A1 (fr) Procede pour la preparation de 4-carboxy-amino-2-substitue-1,2,3,4 tetrahydroquinoleine
FR2693596B1 (fr) Procede de preparation d'une electrode frittee pour un element galvanique.
EP0973719A4 (fr) Procede de preparation d'acides aminocarboxyliques
MA26608A1 (fr) Procede de preparation d'une composition pharmaceutique destinee au traitement de l'insuffisance cardiaque.
MA22955A1 (fr) Procede pour la preparation de nouveaux composes .
MA22860A1 (fr) Procede pour la preparation de nouveaux composes.
FR2764211B1 (fr) Procede de preparation de catalyseurs d'hydrotraitement
MA24182A1 (fr) Procede pour la preparation de 2,4-diaminopyrimidines substituees
MA23309A1 (fr) Procede de preparation de nouveaux composes.
MA23134A1 (fr) Procede pour la preparation d'aryl-piperidine carbinols .
EP1023250A4 (fr) Procede de preparation de 2,6-dialkylnaphtalene
EP0908524A4 (fr) Procede de production d'une substance riche en alpha-monoglucosylhesperidine
EP0692476A3 (fr) Procédé amélioré pour la préparation de N,N'-carbonyldiazoles, spécialement de N,N'-carbonyldiimidazole
DZ2619A1 (fr) Procédé pour la préparation d'acides 4-phényl-4-cyanocyclohexanoïques substitués.
FR2739373B1 (fr) Procede de preparation de catalyseurs d'ammoxydation
FR2659665B1 (fr) Procede d'affinage, notamment de decuivrage, du plomb.
DZ2423A1 (fr) Procédé pour la préparation d'acides 4-phényl-4-cyanocyclohexanoiques substitués.
FR2666234B1 (fr) Cuissard pour la pratique de l'escalade.